Epizyme, Inc.

If you purchased Epizyme, Inc. securities and would like to join the action, please click "Join This Action" below.

EPZM STOCK ALERT: HALPER SADEH LLP IS INVESTIGATING WHETHER THE SALE OF EPIZYME, INC. IS FAIR TO SHAREHOLDERS

June 27, 2022.

New York, New York—Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Epizyme, Inc. (NASDAQ: EPZM) to Ipsen is fair to Epizyme shareholders.

The investigation concerns whether Epizyme and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Epizyme shareholders; (2) determine whether Ipsen is underpaying for Epizyme; and (3) disclose all material information necessary for Epizyme shareholders to adequately assess and value the merger consideration. On behalf of Epizyme shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Scroll to Top